Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1995-12-12
|
| pubmed:abstractText |
Endogenously produced and exogenously administered granulocyte colony-stimulating factor (G-CSF) has correlated with myeloid engraftment in a number of hematopoietic progenitor cell transplantation settings. Given the increased susceptibility of T cell-depleted (TCD) bone marrow transplants (BMT) to graft failure, a cohort of 36 (21 male and 15 female) recipients of TCD BMT was evaluated prospectively during the first month post-transplant for circulating serum G-CSF levels, to examine the correlation between myeloid engraftment and G-CSF levels. All recipients of TCD BM had measurable G-CSF levels, with a median peak level of 1750 pg/ml (range 540-26,250 pg/ml) occurring at a median of 5 days (range 1-18 days) after BM infusion. There was no association between G-CSF kinetics within 1 month post-transplant and the development of primary non-engraftment or secondary graft failure. One patient with primary non-engraftment and 6 patients with secondary graft failure exhibited median G-CSF peak levels of 1600 pg/ml and 1850 pg/ml (range 600-16,250 pg/ml) occurring 5 and 5.5 days (range 4-7 days) after BM infusion, respectively. Additionally, the patient with primary non-engraftment demonstrated a high G-CSF level in response to a low absolute neutrophil count (ANC). An inverse relationship between serial G-CSF levels and concomitant ANC was documented (log G-CSF = 6.19-0.009 ANC, P < 0.001). Higher peak G-CSF levels were associated with older recipient age (P = 0.01) and lower BM cell dose (P = 0.02), while administration of anti-thymocyte globulin post-transplant did not alter G-CSF levels.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
15
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
955-61
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:7581097-Adolescent,
pubmed-meshheading:7581097-Adult,
pubmed-meshheading:7581097-Antilymphocyte Serum,
pubmed-meshheading:7581097-Bone Marrow Transplantation,
pubmed-meshheading:7581097-Child,
pubmed-meshheading:7581097-Child, Preschool,
pubmed-meshheading:7581097-Cohort Studies,
pubmed-meshheading:7581097-Disease Susceptibility,
pubmed-meshheading:7581097-Female,
pubmed-meshheading:7581097-Graft Survival,
pubmed-meshheading:7581097-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:7581097-Humans,
pubmed-meshheading:7581097-Lymphocyte Depletion,
pubmed-meshheading:7581097-Male,
pubmed-meshheading:7581097-Middle Aged,
pubmed-meshheading:7581097-Prospective Studies,
pubmed-meshheading:7581097-T-Lymphocytes,
pubmed-meshheading:7581097-Treatment Outcome
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Serum granulocyte colony-stimulating factor (G-CSF) levels after allogeneic T cell-depleted marrow transplantation.
|
| pubmed:affiliation |
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|